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TDDFTAbstract Half-sandwich organometallic rhodium and iridium complexes [1–6] have been synthe-
sized with ligands L1 (L1 = Pyridin-2-ylmethylene picolinichydrazine) and L2 (L2 = Pyridin-3-
ylmethylene picolinichydrazine). Treatment of [{Cp*MCl2}2] (M = Rh/Ir) with L1 in methanol
has yielded mononuclear cationic complexes such as [{Cp*M(L1N\N)Cl}]PF6 where {M= Rh (1)
and Ir (2)} and dinuclear complexes such as [{(Cp*MCl)2(L1N\N, N\N)}]PF6 where {M=Rh (3)
and Ir (4)} in 1:2 and 1:1 metal dimer to ligand ratios respectively. Reactions of [{Cp*MCl2}2] with
L2 in both 1:2 and 1:1 metal dimer to ligand ratios have yielded two metalla-macrocyclic dinuclear
and dicationic complexes such as [{Cp*M(L2N\NlN)}2](PF6)2 where {M=Rh (5) and Ir (6)}.
Spectroscopic and crystallographic data were used to elucidate the structures of the synthesized
complexes. The in vitro antitumor evaluation of the complexes 1 and 2 by ﬂuorescence basedring the
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two positional isomers of pyridine carbaldehapoptosis study revealed their antitumor activity against Dalton’s ascites lymphoma (DL) cells. The
antibacterial evaluation of complexes 1, 2, 5 and 6 by agar well-diffusion method revealed their sig-
niﬁcant activity against the two species considered viz., Proteus vulgaris (MTCC 426) and Vibrio
parahaemolyticus (MTCC 451) with zone of inhibition up to 43 mm. The docking study with few
key enzymes associated with cancer viz., ribonucleotide reductase, thymidylate synthase, thymidy-
late phosphorylase and topoisomerase II revealed their strong interactions with complexes under
study. Complexes 1–6 exhibited a HOMO (highest occupied molecular orbital) – LUMO (lowest
unoccupied molecular orbital) energy gap from 2.95 eV to 3.59 eV. TDDFT calculations explain
the nature of electronic transitions and found well agreement with the experiments.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There is an immense development in exploiting the medicinal
properties of organometallic compounds in recent years
(Hartinger et al., 2012). The study of the cytotoxic properties
of pentamethylcyclopentadienyl (Cp*) rhodium and iridium
complexes has captured the attention and is growing rapidly
(Schmitt et al., 2008). The spectator Cp* ligand enhances the
stability and cytotoxicity of the complexes, consequently
making them to use as potent enzyme inhibitors (Amouri
et al., 2010). Half-sandwich Rh(III) and Ir(III) tetranuclear
metalla-cycles, complexes of trithiolato-bridged and thiazole
derived N\N donor ligands have shown antiproliferative
activity against human ovarian A2780 cancer cell lines and
Dalton’s ascites lymphoma cells (Gupta et al., 2013a, 2013b).
The resistance acquired by bacteria especially toward the
conventional and purely organic antibiotics attributes for the
reluctance of the pharmaceutical companies to invest money
into the development of new antibiotics which consequently
declines the discovery of the antibiotics during the last two
decades (Nicolaou et al., 2009; Saxena and Gomber, 2010;
Silver, 2011). Metal speciﬁc modes of action of the metallo-
drugs give a hope to overcome the development of antibiotic
resistance and hence there is an urge for the focus on the uti-
lization of organometallic compounds as antibacterial agents
(Gasser et al., 2011; Hartinger and Dyson, 2009; Patra et al.,
2012; Peacock and Sadler, 2008).
Aroyl hydrazone ligands are used as suitable chelators in the
form of orally effective drugs for treating iron overload diseases
like Friedreich’s ataxia (Subhendu et al., 2010). Various organic
molecules containing hydrazine or hydrazone side chain exhibit
good antibacterial activity (Sondhi et al., 2006). Hydrazine
derived ligands are used as drugs for treating cancer, schizophre-
nia and leprosy, etc (Garkani-Nejad and Ahmadi-Roudi, 2002).
The presence of hydrazine-hydrazone (ACOANHAN‚CHA)
functional group plays a signiﬁcant role as pharmaceutical
agents, possessing anti-inﬂammatory, antimalarial, antimicro-
bial, anti-leishmanial, anticonvulsant, anti-tubercular and anti-
tumor activities (Ku¨c¸u¨kgu¨zel et al., 2002).
Hitherto, we have been synthesizing various organometallic
complexes of Cp*Rh and Cp*Ir having nitrogen and oxygen
donor ligands (Govindaswamy et al., 2005; Nongbri et al.,
2009; Prasad et al., 2009; Singh et al., 2005). Recently, we have
reported the complexes of rhodium and iridium with
2-pyridinecarbaldehyde nicotinichydrazone which is also a
positional isomer of the ligands under study. In this ligand
the pyridine of nicotinichydrazone acts as monodentate ligand. et al., Antibacterial, in vitro antitumo
yde picolinic hydrazone ligand. Arabialeaving the two chlorides on the metal i.e., rhodium/iridium
(Gupta et al., 2011). Keeping this in mind we have chosen
the ligands under study by changing the position of the
nitrogen atoms to study the effect of positional isomerism on
mode of binding. Ligand L1 exhibited anticipated binding
modes, whereas L2 exhibited serendipitous binding modes.
The ligands under study were chosen not only based on their
coordination chemistry but also relying on their biological
activity. We have reported the complexes of Cp*Rh and Cp*Ir
carrying salicylaldehyde-2-picolinichydrazone ligand exhibit-
ing in vitro antitumor, antibacterial and ﬂuorescence imaging
properties (Rao et al., 2015). We have substituted salicylalde-
hyde by 2-pyridinecarbaldehyde and 3-pyridine carbaldehyde
moieties to monitor the changes in binding modes as well as
the biological activity in the corresponding rhodium/iridium
complexes. According to our knowledge there are no reports
available in the literature of these complexes with present
ligands under study. Cyclooctadiene complexes of Rh and Ir
with 2-picolyl amine derived Schiff base ligands were synthe-
sized and their electronic properties were explored with DFT
studies (Tejel et al., 2008a, 2008b). In this manuscript, we have
described the synthesis, structural aspects, antibacterial and
antitumor activities of rhodium and iridium complexes of the
two positional isomers i.e., L1 and L2. Ligands and their bind-
ing modes to metal are presented in Chart 1.
2. Experimental section
2.1. Materials and methods
The synthesis and manipulation of the ligands and metal com-
plexes were performed without using any inert atmosphere.
Metal chlorides MCl3nH2O (M=Rh and Ir) were purchased
from Arora Matthey Limited. All the solvents used for
synthesis were dried and distilled prior to use according to
the standard procedures and stored over activated molecular
sieves (Perrin and Armarego, 1996). Precursor compounds
viz., [{Cp*RhCl2}2] and [{Cp
*IrCl2}2] and the ligands L1 and
L2 were prepared by following the literature method
(Armstrong et al., 2003; To¨nnemann et al., 2013). Elemental
analysis was performed on a Perkin-Elmer-2400 CHN ana-
lyzer. Infrared (IR) spectra were recorded on a Perkin-Elmer
983 spectrophotometer by dispersing compounds as KBr disks.
1H NMR spectra were recorded with Bruker Avance II
400 MHz spectrometer. UV–vis spectra were recorded using
Perkin Elmer lambda 25 Spectrophotometer. Single crystals
picked up from the samples were analyzed on a STOE IPDSIIr activity and structural studies of rhodium and iridium complexes featuring the
n Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.10.011
Chart 1 Ligands L1 and L2 used in this study with their various binding modes.
Antibacterial, in vitro antitumor activity and structural studies of rhodium and iridium complexes 3diffractometer/Xcalibur, Eos, Gemini diffractometer using Mo
Ka radiation (k= 0.71073 A˚) in the whole reciprocal sphere.
A numerical absorption correction was based on the crystal
shape originally determined by optical face indexing but later
optimized against equivalent reﬂections using STOE X-shape
software. Crystal structures were determined and solved using
the SHELX software (Sheldrick, 1997). The non-hydrogen
atoms were reﬁned anisotropically using weighted full-matrix
least-square on F2. Figs. 2–6 were drawn with ORTEP-3
(Farrugia, 1997). In complex 6, the solvent molecule was
appeared to be acetone and could not be reﬁned because of
its highly disordered structure. Therefore, the SQUEEZE func-
tion of the PLATON program was applied to the X-ray single
crystal data to eliminate the contribution of the electron
density in the solvent region from the intensity data (Spek,
2003). Final reﬁnement was performed by removing the
contribution of the solvent molecule.
Experimental details of antitumor, antibacterial activity
and computational studies are given in the Supplementary
Information.
2.2. Synthesis of complexes 1–6
2.2.1. Complex [Cp*RhL1(N\N)Cl]PF6 (1)
A mixture of [{Cp*RhCl2}2] (50 mg 0.08 mmol), ligand L1
(36.6 mg, 0.16 mmol) and NH4PF6 (26 mg, 0.16 mmol) in
methanol (20 ml) was stirred at room temperature for 6 h
whereby yellow compound was precipitated out. The resulted
yellow precipitate was ﬁltered and washed with diethyl ether
(2  15 ml) and dried in vacuum. Yield: 70 mg (87%). 1H
NMR (400 MHZ, CDCl3): d= 11.19 (s, 1H, NAH), 8.97 (d,
1H, JHH = 4 Hz, HAPy), 8.65 (m, 1H, HAPy), 8.39 (s, 1H,
‚CAH oleﬁnic), 8.32 (d, 1H, JHH = 4 Hz, HAPy), 8.27 (d,
1H, JHH = 8 Hz, HAPy), 8.02 (t, 1H, JHH = 8 Hz, HAPy),
7.93 (t, 1H, JHH = 8 Hz, HAPy), 7.59 (t, 1H, JHH = 8 Hz,
HAPy), 7.53 (t, 1H, JHH = 8 Hz, HAPy), 1.73 (s, 15H, Cp*).
IR (KBr pellet): 3435 (b) m(NAH), 2926 (m) m(CAH), 1623 (s)
m(C‚O), 1599(s) m(C‚N), 844 m(PAF)str, 558 m(PAF)ben cm
1;
UV/Vis (water) kmax nm (abs) = 234 (0.56), 269 (0.31), 358
(0.19). Anal. Calc. for C22H25ClN4ORhPF6: C, 49.27; H,
5.17; N, 7.18. Found: C, 49.45; H, 5.37; N, 7.35.
2.2.2. Complex [Cp*IrL1(N\N)Cl]PF6 (2)
Complex 2 was prepared in a similar way to complex 1 by tak-
ing [{Cp*IrCl2}2] (50 mg, 0.06 mmol), ligand L1 (29 mg,
0.12 mmol) and NH4PF6 (21 mg, 0.12 mmol). The complex
was obtained as an orange solid. Yield: 52 mg (68%). 1HPlease cite this article in press as: Palepu, N.R. et al., Antibacterial, in vitro antitumo
two positional isomers of pyridine carbaldehyde picolinic hydrazone ligand. ArabianNMR (400 MHZ, DMSO-d6): d= 10.02 (s, 1H, NAH), 8.80
(d, 1H, JHH = 4 Hz, HAPy), 8.47 (d, 1H, JHH = 4 Hz,
HAPy), 8.31 (t, 1H, JHH = 8 Hz, HAPy), 8.23 (m, 2H,
HAPy), 8.17 (s, 1H,‚CAH oleﬁnic), 7.89 (t, 1H, JHH = 8 Hz,
HAPy), 7.80 (t, 1H, JHH = 8 Hz, HAPy), 7.50 (t, 1H,
JHH = 8 Hz, HAPy), 1.69 (s, 15H, Cp*). IR (KBr pellet):
3412 (b) m(NAH), 2924 (m) m(CAH), 1640 (s) m(C‚O), 1618 (s)
m(C‚N), 842 m(PAF)str, 558 m(PAF)ben cm
1; UV/Vis (Water) kmax
nm (abs) = 213 (0.69), 274 (0.37), 370 (0.19), 440 (0.05). Anal.
Calc. for C22H25ClN4OIrPF6: C, 35.99; H, 3.43; N, 7.63;
Found: C, 36.19; H, 3.58; N, 7.82.2.2.3. Complex [(Cp*RhCl)2L1(N\N,N\N)]PF6 (3)
A mixture of [{Cp*RhCl2}2] (50 mg 0.08 mmol), ligand L1
(18.3 mg, 0.08 mmol) and NH4PF6 (26 mg, 0.16 mmol) in
methanol (20 ml) was stirred at room temperature for 6 h
whereby yellow compound was precipitated out. The resulted
yellow precipitate was ﬁltered and washed with diethyl ether
(2  15 ml) and dried in vacuum. Yield: 44 mg (73%). 1H
NMR (400 MHZ, CDCl3 and DMSO-d6): d= 8.97 (s, 1H,
‚CAH oleﬁnic), 8.91 (d, 1H, JHH = 4 Hz, HAPy), 8.58
(m, 1H, HAPy), 8.29 (s, 1H, ‚CAH oleﬁnic), 8.17 (d, 1H,
JHH = 8 Hz, HAPy), 8.12 (d, 1H, JHH = 4 Hz, HAPy), 8.02
(t, 1H, JHH = 8 Hz, HAPy), 7.90 (t, 1H, JHH = 8 Hz,
HAPy), 7.49 (t, 1H, JHH = 8 Hz, HAPy), 7.33 (t, 1H,
JHH = 8 Hz, HAPy), 1.64 (s, 15H, Cp*), 1.61 (s, 15H, Cp*).
IR (KBr pellet): 2922 (m) m(CAH), 1665 (s) m(C‚O), 1603(s)
m(C‚N), 845 m(PAF)str, 558 m(PAF)ben cm
1; UV/Vis (Water)
kmax nm (abs) = 230 (0.65), 270 (0.35), 361 (0.18). Anal. Calc.
for C32H39Cl2F6N4OPRh2: C, 41.90; H, 4.29; N, 6.11. Found:
C, 42.05; H, 4.41; N, 6.30.2.2.4. Complex [(Cp*IrCl)2L1(N\N,N\N)] PF6 (4)
Complex 4 was prepared similar to complex 3 by taking
[{Cp*IrCl2}2] (50 mg, 0.06 mmol), ligand L1 (15 mg
0.06 mmol) and NH4PF6 (21 mg, 0.12 mmol). The complex
was obtained as an orange solid. Yield: 40 mg (68%).
1H NMR (400 MHZ, CDCl3 and DMSO-d6): 8.91 (s, 1H,
‚CAH oleﬁnic), 8.79 (d, 1H, JHH = 8 Hz, HAPy), 8.74
(d, 1H, JHH = 4 Hz, HAPy), 8.19 (d, 1H, JHH = 4 Hz,
HAPy), 8.07 (m, 3H, HAPy), 7.67 (m, 2H, HAPy), 1.62
(s, 15H, Cp*), 1.58 (s, 15H, Cp*); IR (KBr pellet): 2923 (m)
m(CAH), 1611 (s) m(C‚O), 1576 (s) m(C‚N), 843 m(PAF)str, 558
m(PAF)ben cm
1; UV/Vis (Water) kmax nm (abs) = 266 (0.22),
325 (0.13). Anal. Calc. for C32H39Cl2F6N4OPIr2: C, 35.07;
H, 3.59; N, 5.11. Found: C, 35.25; H, 3.76; N, 5.29.r activity and structural studies of rhodium and iridium complexes featuring the
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4 N.R. Palepu et al.2.2.5. Complex [{Cp*RhL2(N\NlN)}2](PF6)2 (5)
A mixture of [{Cp*RhCl2}2] (50 mg, 0.08 mmol), the ligand L2
(29 mg 0.16 mmol) and NH4PF6 (26 mg, 0.16 mmol) in metha-
nol (20 ml) was stirred at room temperature for 6 h. The
resulted orange precipitate was ﬁltered and washed with
diethyl ether (2  15 ml) and dried in vacuum. The complex
was obtained as an orange solid. Yield: 52 mg (65%). 1H
NMR (400 MHZ, CDCl3): d= 9.19 (s, 2H, HAPy), 8.93
(d, 2H, JHH = 4 Hz, HAPy), 8.78 (s, 2H, ‚CAH oleﬁnic),
8.65 (dd, 2H, JHH = 4 Hz, JHH = 4 Hz, HAPy), 8.31 (d, 2H,
JHH = 4 Hz, HAPy), 8.24 (d, 2H, JHH = 8 Hz, HAPy), 7.99
(t, 2H, JHH = 4 Hz, HAPy), 7.93 (t, 2H, JHH = 4 Hz, HAPy),
7.50 (m, 2H, HAPy), 7.40 (t, 2H, HAPy), 1.62 (s, 30H, Cp*);
IR (KBr pellet): 2964 (m) m(CAH), 1643 (s) m(C‚O), 1596 (s)
m(C‚N), 844 m(PAF)str, 560 m(PAF)ben cm
1; UV/Vis (Water),
kmaxnm (abs) = 226 (0.84), 257 (0.77), 353 (0.27). Anal. Calc.
for C44H48F12N8O2P2Rh2: C, 43.44; H, 3.98; N, 9.21. Found:
C, 43.63; H, 4.12; N, 9.38.
2.2.6. Complex [{Cp*IrL2(N\NlN)}2](PF6)2 (6)
Complex 6 was prepared similar to complex 5 by taking
[{Cp*IrCl2}2] (50 mg, 0.06 mmol), the ligand L2 (29 mg
0.12 mmol) and NH4PF6 (21 mg, 0.12 mmol) in methanol
(20 ml). The complex was obtained as yellow solid. Yield:
60 mg (75%). 1H NMR (400 MHZ, DMSO-d6): 9.07 (s, 2H,
HAPy), 8.81 (d, 2H, JHH = 4 Hz, HAPy), 8.75 (d, 2H,
JHH = 4 Hz, HAPy), 8.56 (d, 2H, JHH = 4 Hz, HAPy), 8.53
(s, 1H, ‚CAH oleﬁnic), 8.17 (m, 2H, HAPy), 8.02 (d, 2H,
JHH = 8 Hz, HAPy), 7.81 (t, 2H, JHH = 4 Hz, HAPy), 7.75
(m, 4H, HAPy), 1.56 (s, 30H, Cp*); IR (KBr pellet): 2926
(m) m(CAH), 1628 (s) m(C‚O), 1596 (s) m(C‚N), 843 m(PAF)str,
558 m(PAF)ben cm
1; UV/Vis (Water), kmax nm (abs) = 263
(0.74), 400 (0.10). Anal. Calc. for C44H48F12N8O2P2Ir2: C,
37.88; H, 3.47; N, 8.03. Found: C, 37.98; H, 3.67; N, 8.21.
3. Results and discussion
3.1. Synthesis and characterization
Complexes 1–6 are obtained by treating ligands L1 and L2
with the corresponding precursor compounds in methanol
(Scheme 1). All the complexes are isolated as their hexaﬂuo-
rophosphate salts and are obtained as yellowish to orange
powders. They are soluble in polar organic solvents such as
dichloromethane, methanol and acetonitrile. They are also sol-
uble in water (1 mg/mL) but insoluble in nonpolar solvents
such as diethyl ether and hexane. Reaction of rhodium and
iridium metal precursors with L1 in 1:2 and 1:1 ratios yielded
mononuclear complexes 1 and 2, and dinuclear complexes 3
and 4 respectively. Reaction of Rh and Ir metal precursors
and ligand L2 in both 1:1 and 1:2 ratios yielded the dinuclear
complexes 5 and 6 respectively.
3.2. Binding modes of ligands
The two ligands used in this study viz., L1 and L2 are obtained
by condensing picolinic hydrazine with 2-pyridine-
carbaldehyde and 3-pyridinecarbaldehyde respectively. The
ligand L1 binds to the metal in chelating bidentate manner.
There are two possibilities for the ligand to bind to the metalPlease cite this article in press as: Palepu, N.R. et al., Antibacterial, in vitro antitumo
two positional isomers of pyridine carbaldehyde picolinic hydrazone ligand. Arabiaviz., the chelating site of picolinamide and pyridin-2-
ylmethylene parts of the ligand. In case of complexes 1 and
2, the metal binds to the two nitrogen atoms of the pyridin-
2-ylmethylene part of the ligand in mode 1 as shown in Chart 1
forming mononuclear complexes. The preferential binding of
the metal at pyridin-2-ylmethylene part in mode 1 has led to
the formation of cationic complexes since the two nitrogen
atoms are neutral. If the metal binds to the two nitrogen atoms
of the picolinamide part it would result in the formation of
neutral complexes which was not observed. The dinuclear
complexes 3 and 4 are resulted by the binding of metals at
the two chelating sites of the ligand L1 as in mode 2 by depro-
tonation of N-H proton of the picolinamide part.
The ligand L2 acts as both chelating and bridging nitrogen
donor (N\NlN) as in the case of complexes 5 and 6. Metal
can bind to the monodentate pyridine of pyridin-2-
ylmethylene part of the ligand in mode 3 (Chart 1). The bridg-
ing nature of the ligand L2 is responsible for the displacement
of a chloride from the metal center yielding the ionic com-
plexes (5 and 6) with two PF6 counteranions. In general, the
monodentate pyridine binds to metal rhodium/iridium leaving
the two chlorides on metal as reported previously by our group
(Gupta et al., 2011). Contrastingly, in complexes 5 and 6 the
monodentate pyridine has substituted the chloride on
rhodium/iridium present at the chelating portion and has
culminated to the formation of dinuclear complexes with three
nitrogen atoms surrounding to each metal.
3.3. Spectral studies
3.3.1. Mononuclear complexes 1 and 2
The IR spectra of mononuclear complexes 1 and 2 show the
stretching frequencies of NAH at 3435 cm1 and 3512 cm1
respectively. Carbonyl stretching frequencies are observed at
1623 cm1 and 1640 cm1 respectively. The 1H NMR spec-
trum of complex 1 displays a singlet at d 1.73 corresponds to
methyl protons of Cp*, a singlet at d 11.19 corresponds to
NAH proton and a singlet at d 8.39 corresponds to oleﬁn
CAH proton which conﬁrms the presence of both ligand and
metal parts. Three doublets and one multiplet at d 8.65–7.58
and four triplets at d 8.02–7.53 corresponding to the pyridine
rings are observed. The presence of signals corresponding to
ten protons of the ligand and singlet corresponding NAH
proton has suggested that the metal (Rh/Ir) is binding to the
two nitrogen atoms of the pyridin-2-ylmethylene part of the
ligand. The 1H NMR spectrum of the complex 2 displays sin-
glet resonances at d 1.69, d 10.02 and d 8.17 corresponding to
the methyl protons of Cp*, NAH proton and oleﬁn CAH
proton which conﬁrms the presence of both ligand and the
metal parts. Two doublets and one multiplet at d 8.80, d 8.47
and d 8.25 respectively and four triplets at d 8.31–7.50 corre-
sponding to pyridine rings conﬁrm the formation of complex.
3.3.2. Dinuclear complexes 3 and 4
The IR spectra of the dinuclear complexes 3 and 4 show car-
bonyl stretching frequencies at 1665 cm1 and 1611 cm1
respectively and exhibit signiﬁcant difference in carbonyl
stretching frequencies compared to that of mononuclear com-
plexes. In rhodium complex (complex 3) it has increased,
whereas in iridium complex (complex 4) it has decreased
compared to their corresponding mononuclear complexes. Inr activity and structural studies of rhodium and iridium complexes featuring the
n Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.10.011
Scheme 1 Schematic presentation of the synthesis of complexes 1–6.
Antibacterial, in vitro antitumor activity and structural studies of rhodium and iridium complexes 5the 1H NMR spectra of complexes 3 and 4, the absence of
characteristic NAH proton signal supports the binding of
the second metal Rh/Ir at the picolinamide part of the ligand
by deprotonating the NAH proton. Complex 3 exhibits
oleﬁnic singlet at d 8.97, three doublets at d 8.91–8.17, four tri-
plets at d 8.02–7.33 and a multiplet at d 8.58 corresponding to
the ligand. Complex 4 exhibits three doublets around d 8.79, d
8.74 and d 8.19, two multiplets of three protons and two pro-
tons respectively at d 8.07 and d 7.67 correspond to ligand. The
two singlet resonances of the two Cp* rings in complex 3 are
observed at d 1.64 and d 1.61 and those in complex 4 are
observed at d 1.62 and d 1.58 which justiﬁes the formation
of the dinuclear complexes.
3.3.3. Dinuclear metalla-macrocyclic complexes 5 and 6
The IR spectra of complexes 5 and 6 display carbonyl stretch-
ing frequencies at 1643 cm1 and 1628 cm1 respectively. In
complex 5, two singlets at d 9.19 and d 8.78 correspond to
two protons of pyridine (proton on C(22) see Fig. 5) and
two oleﬁnic protons are observed. A doublet at d 8.93, a
doublet of doublet at d 8.65, two doublets at d 8.31 and d
8.24, three triplets at d 7.99, d 7.93 and d 7.40 and a multiplet
at d 7.50 corresponds to pyridine rings are also observed.
Complex 6 exhibits two singlets at d 9.07 and d 8.53 correspondPlease cite this article in press as: Palepu, N.R. et al., Antibacterial, in vitro antitumo
two positional isomers of pyridine carbaldehyde picolinic hydrazone ligand. Arabianto two protons of pyridine (proton on C(22) see Fig. 6) and
oleﬁnic protons respectively. Four doublets at d 8.81–8.02
and two triplets at d 8.17 and d 7.81 and a multiplet at d
7.75 corresponds to pyridine rings are also observed. In com-
plexes 5 and 6 the binding of the metal at picolinic part of
the ligand by deprotonation is corroborated by the absence
of NAH proton in 1H NMR spectra. The cationic nature of
the complexes 1–6 with PF6 counterion is supported by IR
spectroscopy with the presence of characteristic PAF stretch-
ing frequencies at 842 cm1 to 845 cm1.
3.4. UV–visible spectral studies
UV–visible spectra of complexes 1–6 were recorded in water in
20 lM solution and the electronic spectra of these complexes
are depicted in (Fig. 1). The electronic spectra display bands
at 213 nm to 274 nm and 325 nm to 370 nm in ultraviolet
region. The wavelengths below 300 nm are attributed to
intraligand p–p* transitions. In complexes 2 and 6 wavelengths
at 440 nm and 400 nm respectively observed in visible region
are assigned to a mixture of metal-to-ligand charge transfer
(MLCT) transition from metal t2g orbitals to p* orbitals of
the ligand and intraligand charge transfer (ILCT) transitions
(Table S4) (Chantzis et al., 2014).r activity and structural studies of rhodium and iridium complexes featuring the
Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.10.011
Figure 1 UV–visible spectra of complexes 1–6 recorded in water
at 20 lM concentration.
Figure 3 Molecular structure of complex 2 with atom number-
ing scheme. Thermal ellipsoids are depicted with 50% probability
level. Hydrogen atoms (except on N(3)), PF6 and acetone are
omitted for clarity.
6 N.R. Palepu et al.3.5. Structural studies by X-ray crystallography
The molecular structures of complexes 1, 2, 3, 5 and 6 with
various binding modes of the ligands were conﬁrmed by
X-ray structural analyses. Structure of complex 1 is found to
have a disorder in the ellipsoids of Cp* ring and consequently
has a high R value and its structure is presented only to illus-
trate the structure and connectivity of atoms. ORTEP draw-
ings with an atom labeling scheme are shown in (Figs. 2–6).
The summary of the crystallographic data for these complexes
is presented in Table 1. Selected bond lengths and angles are
presented in Table 2.
3.5.1. Molecular structures of mononuclear complexes 1 and 2
Yellow crystals of complex 1 suitable for single-crystal X-ray
structure analysis were obtained by diffusing hexane into a
chloroform solution of the complex. Orange crystals of com-
plex 2 suitable for single-crystal X-ray structure analysis wereFigure 2 Molecular structure of complex 1 with atom number-
ing scheme. Thermal ellipsoids are depicted with 50% probability
level. Hydrogen atoms (except on N(3)), PF6 and chloroform are
omitted for clarity.
Figure 4 Molecular structure of complex 3 with atom number-
ing scheme. Thermal ellipsoids are depicted with 50% probability
level. Hydrogen atoms and PF6 are omitted for clarity.
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complex. In complex 1, Cp* ring to Rh(1)centroid distance is
1.789 A˚. The bond lengths of Rh(1)AN(1), Rh(1)AN(2) and
Rh(1)ACl(1) are 2.113(12) A˚, 2.106(11) A˚ and 2.387(4) A˚
respectively. The bite angles around the metal viz., N(1)ARh
(1)AN(2), N(1)ARh(1)ACl(1) and N(2)ARh(1)ACl(1) are
76.0(5), 83.8(4) and 86.9(3) respectively indicate a slight distor-
tion from the octahedral bond angle which is because of the
strain existing around the metal with ligand. In complex 2,
Cp* ring to Ir(1)centroid distance is 1.784 A˚. Ir(1)AN(1), Ir
(1)AN(2) and Ir(1)ACl(1) bond distances are 2.102(4) A˚,
2.091(4) A˚ and 2.383(14) A˚ respectively. The bite angles
around the metal center viz., N(1)AIr(1)AN(2), N(1)AIr(1)A
Cl(1) and N(2)AIr(1)ACl(1) are 75.54(15), 82.72(13) and
88.75(12) respectively and thus complex 2 is found to have
the similar geometrical features of complex 1.r activity and structural studies of rhodium and iridium complexes featuring the
n Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.10.011
Figure 5 Molecular structure of complex 5 with atom numbering scheme. Thermal ellipsoids are depicted with 50% probability level.
Hydrogen atoms, hexane and PF6 counterions are omitted for clarity.
Figure 6 Molecular structure of complex 6 with atom numbering scheme. Thermal ellipsoids are depicted with 50% probability level.
Hydrogen atoms and PF6 counterions are omitted for clarity.
Antibacterial, in vitro antitumor activity and structural studies of rhodium and iridium complexes 73.5.2. Molecular structure of dinuclear complex 3
Yellow crystals suitable for single-crystal X-ray structure anal-
ysis were obtained by diffusing hexane into a chloroform solu-
tion of the complex. In complex 3, Cp* ring to Rh(1)centroid and
Cp* ring to Rh(2)centroid distances are 1.797 A˚ and 1.790 A˚
respectively. Metal to nitrogen bond distances viz., Rh(1)AN
(1), Rh(1)AN(2), Rh(2)AN(3) and Rh(2)AN(4) are 2.119(3),
2.153(3), 2.090(4) and 2.131(3) respectively. Metal to chloride
distances viz., Rh(1)ACl(1) and Rh(2)ACl(2) are 2.388(10)
and 2.390(11) respectively. The bite angles around the metal
Rh(1) viz., N(1)ARh(1)AN(2), N(1)ARh(1)ACl(1), N(2)ARh
(1)ACl(1) are 76.57(13), 82.89(10) and 88.23(9) respectively.
Bite angles around the metal Rh(2) viz., N(3)ARh(2)AN(4),
N(3)ARh(2)ACl(2) and N(4)ARh(2)ACl(2) are 76.34(14),
85.52(10) and 89.20(9) respectively. Bond angle around the
carbonyl carbon i.e., C(15)AC(16)AN(2) is 116.9(4). In the
crystal structure of complex 3 the electron density mapsPlease cite this article in press as: Palepu, N.R. et al., Antibacterial, in vitro antitumo
two positional isomers of pyridine carbaldehyde picolinic hydrazone ligand. Arabiansuggests that oxygen is present on both the sites i.e., on C
(16) and C(17). The molecule ﬂips 35% of the time one side
and 65% of the time on the other side which results in oxygen
and hydrogen appearing as if they are present on the same site,
but they both are never at the same time. Only one of the two
either oxygen or hydrogen is ever present on the same site at a
given time. For instance, if oxygen is on C(16) this forces
hydrogen atom to be attached to C(17) and if oxygen is on
C(17) this forces hydrogen atom to be attached to C(16)
(Fig. 4).
3.5.3. Molecular structures of dinuclear metalla-macrocyclic
complexes 5 and 6
Orange crystals of complexes 5 and 6 suitable for single-crystal
X-ray structure analysis were obtained by diffusing hexane
into an acetone solution of the complex. In complex 5, Cp*
ring to Rh(1)centroid distance is 1.788 A˚. The bond length ofr activity and structural studies of rhodium and iridium complexes featuring the
Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.10.011
Table 1 Crystallographic and structure reﬁnement parameters for complexes 1, 2, 3, 5 and 6.
1 [CHCl3] 2 [CH3COCH3] 3 5 [C6H14] 6
Empirical formula C23H26Cl4F6N4OPRh C47H56Cl2F12Ir2N8O3P2 C32H39Cl2F6N4OPRh2 C25H31F6N4OPRh C44H48F12Ir2N8O2P2
Formula weight 764.16 1526.24 917.36 651.42 1395.24
Temperature (K) 293(2) 293(2) 293(2) 293(2) 293(2)
Wavelength (A˚) 0.71073 0.71073 0.71073 0.71073 0.71073
Crystal system Monoclinic Triclinic Monoclinic Orthorhombic Orthorhombic
Space group P2(1)/n P1 P2(1)/c Fdd2 Fdd2
Unit cell dimensions (A˚, )
a 8.4541(17) 11.2469(3) 8.3982(2 55.595(11) 55.482(11)
b 16.316(3) 15.7675(5) 13.5152(4) 12.984(3) 12.950(3)
c 22.079(4) 18.1783(8) 32.0204(9) 15.109(3) 15.157(3)
a 90.00 111.367(3) 90.00 90.00 90.00
b 99.02(3) 106.373(3) 96.113(2) 90.00 90.00
c 90.00 97.120(3) 90.00 90.00 90.00
Volume (A˚3), Z 3007.8(10), 4 2786.12(17), 2 3613.76(17), 4 10906(4) 10890(4), 8
Calculated density
(mg m–3)
1.687 1.819 1.68 1.587 1.702
Absorption coeﬃcient
(mm1)
1.039 5.012 1.169 0.752 5.024
Crystal size (mm3) 0.2  0.15  0.1 0.22  0.12  0.17 0.11  0.18  0.29 0.8  0.7  0.7 0.35  0.32  0.22
Scan range 3.07–26.37 3.03–26.37 3.08–26.37 1.47–24.89 1.47–24.83
Reﬂections collected 13184 21050 7376 1099 44427
Independent
reﬂections (Rint)
6142 (0.0278) 11361(0.0257) 6388(0.0309) 4695(0.0612) 4700 (0.0374)
Reﬁnement method Full-matrix least-
squares on F2
Full-matrix least-
squares on F2
Full-matrix least-
squares on F2
Full-matrix least-
squares on F2
Full-matrix least-
squares on F2
Data/
restraints/parameters
6142/0/357 11361/0/698 6388/0/459 4695/0/340 4700/0/322
Goodness-of-ﬁt on F2 1.157 1.036 1.104 0.849 1.071
Final R indices
[I > 2r(I)]a
R1 = 0.1084,
wR2 = 0.2953
R1 = 0.0334,
wR2 = 0.0464
R= 0.0435,
wR2 = 0.0919
R= 0.0364,
wR2 = 0.0557
R1 = 0.0319,
wR2 = 0.0845
R indices (all data) R1 = 0.1258,
wR2 = 0.3144
R1 = 0.0732,
wR2 = 0.0794
R1 = 0.0534,
wR2 = 0.0957
R1 = 0.0583,
wR2 = 0.0595
R1 = 0.0341,
wR2 = 0.0856
Largest diﬀerence
peak and hole (e A˚3)
5.547 and 1.471 0.923 and 0.946 0.805 and 0.699 0.450 and 0.464 0.728 and 1.455
a Structures were reﬁned on F0
2: wR2 = [R[w(F0
2  Fc2)2]/Rw (F02)2]1/2, where w1 = [R(F02) + (aP)2 + bP] and P= [max(F02, 0) + 2Fc2]/3.
8 N.R. Palepu et al.Rh(1)AN(1), Rh(1)AN(2) and Rh(1)AN(4) is 2.096(4), 2.072
(4) and 2.114(4) respectively. The bite angles around the metal
viz., N(1)ARh(1)AN(2), N(1)ARh(1)AN(4) and N(2)ARh
(1)AN(4) are 76.85(18), 88.76(17) and 89.36(16) respectively.
In complex 6, Cp* ring to Ir(1)centroid distance is 1.788 A˚. Bond
lengths of Ir(1)AN(1), Ir(1)AN(2) and Ir(1)AN(4) are 2.068(7)
A˚, 2.088(5) A˚ and 2.135(5) A˚ respectively. The bite angles
around the metal viz., N(1)AIr(1)AN(2), N(1)AIr(1)AN(4)
and N(2)AIr(1)AN(4) are 76.6(2), 86.5(2) and 87.5(2) respec-
tively. In complex 6, the electron density of a disordered sol-
vent which is appeared to be acetone is removed through the
SQUEEZE command on PLATON. In complexes 5 and 6
the metal atom (Rh/Ir) is surrounded by three nitrogen atoms,
out of them two nitrogen atoms are in chelating fashion from
one ligand and third nitrogen atom from another ligand in
bridging fashion. The carbonyl bond lengths in complexes 1,
2, 3, 5 and 6 viz., C(17)AO(1), C(17)AO(1), C(16)AO(1), C
(16)AO(1) and C(16)AO(1) respectively are 1.166(16) A˚,
1.277(10) A˚, 1.205(6) A˚, 1.212(6) A˚ and 1.221(10) A˚ support
the existence of the ligand in keto form. In complexes 1 and
2 the presence of N(3)AH(3) proton with a distance of 0.86
A˚ corroborates the presence of NAH bond which is not
deprotonated by metal. In contrast, the NAH bond is absent
in the crystal structures of complexes 3, 5 and 6 because it isPlease cite this article in press as: Palepu, N.R. et al., Antibacterial, in vitro antitumo
two positional isomers of pyridine carbaldehyde picolinic hydrazone ligand. Arabiadeprotonated while forming the complexes. Thus in complexes
1 and 2 the ligand is neutral whereas in complexes 3, 4, 5 and 6
the ligand is anionic which is attributed by the deprotonation
of ligand by metal in forming dinuclear complexes. Complexes
1, 2 and 5 have crystallized with chloroform, acetone and
hexane solvent molecules respectively. The hydrogen bonds
formed by solvent molecules and counterions with complexes
are depicted in (Fig. 7) and the corresponding bond lengths
and angles are given in Table 1. All the complexes possess a
‘‘piano-stool’ geometry with Cp* ring on the top as seat. In
complexes 1–4 the positions of three legs are occupied by
two nitrogen atoms from the ligand and one chloride, whereas
in complexes 5 and 6, the three nitrogen atoms from the ligand,
two in chelating fashion and one as monodentate satisfy the
positions of the three legs. The metal chloride, PAF, the
CAC bond lengths within the Cp* ring, CAMe distances and
metal to centroid distances are usual and are consistent with
the values reported previously (Prasad et al., 2008).
3.6. Apoptosis analysis in DL and normal PBMC cells
The nuclei of control DL cells are round in shape with uniform
green ﬂuorescence without any membrane deformities prior to
the treatment with complexes 1 and 2. Cisplatin treatment ofr activity and structural studies of rhodium and iridium complexes featuring the
n Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.10.011
Table 2 Selected bond distances (A˚) and angles () for complexes 1, 2, 3, 5 and 6.
1 2 3 5 6
Bond distances (A˚)
M(1)ACp*CNT 1.789 1.784 1.797 1.788 1.824
M(2)ACp*CNT – – 1.790 – –
M(1)AN(1) 2.113(12) 2.102(4) 2.119(3) 2.096(4) 2.068(7)
M(1)AN(2) 2.106(11) 2.091(4) 2.153(3) 2.072(4) 2.088(5)
M(2)AN(3) – – 2.090(4) – –
M(2)AN(4) – – 2.131(3) – –
M(1)ACl(1) 2.387(4) 2.383(14) 2.388(10) – –
M(2)ACl(2) – – 2.390(11) – –
C(16)/(17)/(32)AO(1) 1.166(16) 1.205(6) 1.277(10) 1.212(6) 1.221(10)
N(2)AN(3)/N(4) 1.348(15) 1.392(5) 1.383(4) 1.384(5) 1.410(8)
Bond Angles ()
N(1)AM(1)AN(2) 76.0(5) 75.54(15) 76.57(13) 76.85(18) 76.6(2)
N(1)AM(1)ACl(1) 83.8(4) 82.72(13) 82.89(10) – –
N(2)AM(1)ACl(1) 86.9(3) 88.75(12) 88.23(9) – –
N(3)ARh(2)AN(4) – – 76.34(14) – –
N(3)ARh(2)ACl(2) – – 85.52(10) – –
N(4)ARh(2)ACl(2) – – 89.20(9) – –
N(1)ARh(1)AN(4) – – – 88.76(17) 86.5(2)
N(2)ARh(1)AN(4) – – – 89.36(16) 87.5(2)
*CNT= Centroid.
Antibacterial, in vitro antitumor activity and structural studies of rhodium and iridium complexes 9cells for 12 h has shown many apoptotic features with mem-
brane blebbing and fragmented nuclei. Complexes 1 and 2
have shown moderate to high apoptotic features which include
membrane blebbing, swelling, chromatin condensation and cell
membrane abnormality with fragmented nuclei. After treat-
ment with the complex 1 at lower dose viz., 20 lg/mL
(0.310 mM) and 40 lg/mL (0.620 mM) the appearance of
membrane folding, blebbing and chromatin condensation is
observed. At higher doses viz., 60 lg/mL (0.930 mM), 80 lg/
mL (1.24 mM) and 100 lg/mL (1.55 mM) severe cell mem-
brane abnormalities with fragmented nucleus and nucleolus,
pyknosis and cytoplasmic vacuoles are noticed (Fig. 8a). Sim-
ilar changes in the cells are observed after treatment with the
complex 2 at lower dose viz., 20 lg/mL (0.272 mM) and
40 lg/mL (0.544 mM) and higher doses viz., 60 lg/mL
(0.816 mM), 80 lg/mL (1.08 mM) and 100 lg/mL (1.36 mM).
Treated cells display a phenomenon of early apoptosis as
shown by the emitted red ﬂuorescence in both the cases. Com-
plexes 1 and 2 show moderate apoptotic effect (Fig. 8b) atFigure 7 Depiction of the interactions of solvent molecules
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cell death. Rhodium and iridium complexes of salicylaldehyde
2-picolinichydrazone ligand have shown only 12% and 10%
apoptotic cell death at this concentration (Rao et al., 2015).
It suggests that complexes that are obtained by the substitution
of salicylaldehyde by 2-pyridine carbaldehyde have shown
increased apoptosis by 100% and 300% respectively.
After treatment with complexes 1 and 2, the apoptotic cell
death in normal PBMC cells was found to be lesser as com-
pared to cisplatin (reference drug) (Fig. 8c). At a concentration
of 100 lg/mL complexes 1 and 2 have shown 14% and
10% apoptotic cell death on normal cells. The cytotoxicity
of complexes 1 and 2 on normal cells has been observed as half
of their activity on the DL tumor cells.
3.7. Antibacterial activity
The antibacterial potential of the four metal complexes 1, 2, 5
and 6 is evaluated according to their zone of inhibition againstand counterions with complexes in complexes 1, 2 and 5.
r activity and structural studies of rhodium and iridium complexes featuring the
Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.10.011
Figure 8 (a) Morphological features of apoptotic and viable Dalton’s lymphoma cells stained with acridine orange and ethidium
bromide. Control DL cells are green and more or less round in shape indicating viable cells. Green nuclei are viable cells and red/orange
nuclei indicate apoptotic cells. Scale bar: 50 lM. (b) Quantitative analysis of apoptotic cell death in DL cells. (c) Apoptotic cell death in
normal peripheral blood mononuclear cells (PBMC) of normal mice in response to two complexes with 12 h incubation period. Note:
Cisplatin was used as positive reference drug. Results are expressed as mean ± S.D., n= 3, One way ANOVA, *P 6 0.05 as compared
with cisplatin.
10 N.R. Palepu et al.the two test organisms. The concentration of every complex
used in the activity study is 10 lg/mL and 50 lL solution of
the complex is taken in the bore of the agar. The results in
terms of zone of inhibition are compared with the activity of
the standards where Amoxicillin (10 lg/mL) was used as pos-
itive control and sterilized Milli-Q water was a negative con-
trol. There are no zones of inhibition obtained around the
negative control wells on agar, whereas in the wells containingFigure 9a Zones of inhibition around the wells by complexes under s
study whereas a and b are positive and negative controls respectively.
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are found. Complexes 1, 2, 5 and 6 have shown zones of inhi-
bition 26 mm, 43 mm, 25 mm and 29 mm respectively against
Proteus vulgaris (MTCC 426). Complexes 1, 2, 5 and 6 have
shown zone of inhibition 35 mm, 34 mm, 30 mm and 35 mm
respectively against Vibrio parahaemolyticus (MTCC 451)
(Fig. 9a). These results reveal that all the four complexes are
potent bactericidal against the two bacteria tested.tudy. In ﬁgure, numbers 1, 2, 5 and 6 refer to the complexes under
r activity and structural studies of rhodium and iridium complexes featuring the
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Figure 9b Antagonistic activity of complexes 1, 2, 5 and 6
against the test bacterial species.
Antibacterial, in vitro antitumor activity and structural studies of rhodium and iridium complexes 11In the case of activity against P. vulgaris (MTCC 426) com-
plexes 2 and 6 are more effective than the positive control
Amocixillin. Complexes 1 and 5 are less effective than that
of positive control. Among the four complexes, complex 2
has shown the highest activity with 43 mm and complex 5 is
the least with 25 mm. The activity of the four complexes
against P. vulgaris (MTCC 426) has followed the order com-Figure 10a Docking structure of thymidylate phosphorylase enzym
Deoxyuridine 50-monophosphate, c and d show interactions with comp
the hydrogen bonds.
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Besides the enhancement in antitumor activity, there has been
a tremendous improvement in antibacterial activity of the
complexes of Rh and Ir obtained by substituting the salicy-
laldehyde by pyridine carbaldehyde. The Rh and Ir complexes
of salicylaldehyde 2-picolinichydrazone (Rao et al., 2015) have
shown no activity with P. vulgaris (MTCC 426) and V. para-
haemolyticus (MTCC 451) but the corresponding Rh and Ir
complexes obtained with ligands under study which were
obtained by substituting salicylaldehyde by 2-pyridine car-
baldehyde and 3-pyridine carbaldehyde have shown profound
activity with zones of inhibition from 25 mm to 43 mm. This is
probably because in the former case the complexes are neutral
and in the latter they are ionic. The ionic nature of the com-
plexes might have facilitated them for entering the cell crossing
the membrane.
In case of activity against V. parahaemolyticus (MTCC
451), the complexes under study have shown signiﬁcantly
better activity than positive control. The positive control has
shown only 1 mm zone of inhibition. Complexes 1 and 6 have
shown the highest activity among the four complexes with a
zone of inhibition 35 mm. The activity of four complexes
against V. parahaemolyticus (MTCC 451) is found in the
following order complex 1 complex 6> complex 2>
complex 5.e. Here, a and b show interactions with reference ligand i.e., 20-
lex 6. Hydrogen atoms are omitted for clarity. Dotted lines indicate
r activity and structural studies of rhodium and iridium complexes featuring the
Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.10.011
12 N.R. Palepu et al.3.8. Theoretical studies
3.8.1. Docking analysis
Molecular docking study is carried out to understand the pos-
sible interaction(s) between proteins and ﬁve complexes viz., 1,
2, 3, 5 and 6. The protein structures considered in this study
viz., ribonucleotide reductase, thymidylate synthase, thymidy-
late phosphorylase and topoisomerase II are associated with
cancer progression. The mechanistic chemistry of these key
enzymes is highly expressed and closely involved at various
stages of cell multiplication and hence responsible for the
propagation of cancer. Moreover, their inhibition by various
chemotherapeutic agents is associated with the inhibition of
cancer growth and invasion (Singh and Bhardwaj, 2008).
Therefore, in the present study these enzymes are used for
molecular docking to investigate the possible binding with
newly synthesized complexes. The docking studies have
revealed that all the complexes tested interact with enzymes
at their active pocket and their hydrogen bonding interactions
are given in Table S1. Molecular docking study has shown that
complex 1 could dock with ribonucleotide reductase and shows
three hydrogen bond interactions with three different amino
acids viz., Arg 251A, Arg 160A, Ser 213A and shows strong
interaction with thymidine phosphorylase and renders sevenFigure 10b Docking structure of thymidylate synthase enzyme. H
Deoxyuridine 50-monophosphate, c and d show interactions with comp
hydrogen bonds.
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Ser 217A, Arg 202A, Leu 148A, Lys 221A and four hydrogen
bonds with thymidylate synthase with amino acids viz., Asn
229, Ser 232, Glu 60 and ﬁve hydrogen bonds with topoiso-
merase II with amino acids viz., Gln 17A, Tyr 28A, Thr 27B,
Tyr 144A, Tyr 28B. Complex 6 shows strong interactions with
thymidine phosphorylase with six hydrogen bonds with amino
acids viz., Ser 117A, Tyr 199A, Thr 154A, Ser 144A (Figs. 10a,
10b, S1 and S2). The comparative binding results are shown in
Table S2.
3.9. Density Functional Theory (DFT) calculations
3.9.1. Electronic properties
DFT computation of the complexes 1–6 has been performed
with optimized geometry to correlate the electronic structure
with the observed electronic spectra. HOMO and LUMO
energy gaps in complexes 1–6 are found as 3.59 eV, 3.37 eV,
3.26 eV, 2.95 eV, 3.54 eV and 3.50 eV respectively. The energy
gap of complex 4 is found lesser compared to the others. In
complexes 1–6, HOMO and HOMO1 energy gaps are found
as 0.23 eV, 0.27 eV, 0.15 eV, 0.29 eV, 0.09 eV and 0.05 eV
respectively (Table S3). The TDFFT results including the cal-
culated absorption features, absorption wavelength (nm), andere, a and b show interactions with reference ligand i.e., 20-
lex 1. Hydrogen atoms are omitted for clarity. Dotted lines indicate
r activity and structural studies of rhodium and iridium complexes featuring the
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Scheme 2 Schematic presentation of Host–guest complexes considered for the theoretical study.
Antibacterial, in vitro antitumor activity and structural studies of rhodium and iridium complexes 13major transition and charge transfer assignments are given in
Table S4. The contributions of the selected moieties of the
model complexes 1–6 to the individual molecular orbitals were
calculated by a Mulliken population analysis and are listed in
the 1.3.2 of SI and Table S5. In complex 1, an absorption peak
at k= 270.2 nm results from a major transition from
HOMO9 to LUMO (71%) and an absorption peak at
k= 356.8 nm results from a transition from HOMO2 to
LUMO (76%) and HOMO3 to LUMO (15%) which attri-
bute for ILCT transitions. In complex 2, an absorption peak
at k= 270.7 nm results from a major transition from
HOMO3 to LUMO+1 (56%) which attribute for LMCT
and ILCT transitions. An absorption peak at k= 370.4 nm
results from a major transition from HOMO2 to LUMO
(53%), HOMO1 to LUMO+1 (23%) which suggests the
LMCT and ILCT transitions. An absorption peak at
k= 424.2 nm results from a major transition from HOMO1
to LUMO (92%) which contributes for MLCT transitions. In
complex 3, an absorption peak at k= 361.19 nm results from
a major transition from HOMO6 to LUMO+1 (31%),
HOMO5 to LUMO (12%) which contributes for XLCT
(X‚Cl) chloride to ligand charge transfer and MLCT transi-
tions. In complex 4, an absorption peak at k= 328 nm results
from a major transition from HOMO1 to LUMO+3 (52%)
which contributes for MLCT transition. In complex 5, an
absorption peak at k= 355 nm results from a major transition
from HOMO2 to LUMO+5 (22%) and HOMO3 to
LUMO+4 (14%) which contributes for MLCT and
ILCT transitions. In complex 6, an absorption peak at
k= 400.8 nm results from a major transition from HOMO1
to LUMO (67%) which suggests the ILCT transition.Please cite this article in press as: Palepu, N.R. et al., Antibacterial, in vitro antitumo
two positional isomers of pyridine carbaldehyde picolinic hydrazone ligand. Arabian3.9.2. Host guest chemistry of complexes 5 and 6
Complexes 5 and 6 are metalla-macrocycles which are formed
by the substitution of the metal chloride by ligand (L2) and
binding in chelating and bridging modes. Complexes 5 and 6
have formed a cycle including the metal atoms (Rh/Ir). The
structure has got a resemblance with the porphyrin ring of
course with metal atoms present in the ring. We have carried
out a theoretical study by inserting various metal ions viz.,
Li+, Na+, Mg+2, Cu+, Ni+2 and Zn+2 inside the ring to
check the feasibility of the insertion of metal ion inside the
ring. Metal ion inserted derivatives of the complex 5 with
Li+, Na+, Mg+2, Cu2+, Ni+2 and Zn+2 are represented as
5a–5f. Metal ion inserted derivatives of the complex 6 with
Li+, Na+, Mg+2, Cu2+, Ni+2 and Zn+2 are represented as
6a–6f (Scheme 2). Complexes of rhodium with the optimized
structures revealed that lithium, sodium and magnesium ions
can bind to the two oxygen atoms of the two ligands so that
it lies above the plane of the ring. In case of copper, nickel
and zinc ions the metal enters inside the ring and binds to
two nitrogen atoms present in the trans position (Figs. S4
and S5). We are investigating for the practical implementation
of the theoretical results.
4. Conclusions
The preferential binding of the metal (Rh and Ir) toward
pyridin-2-ylmethylene part of the ligand in L1 results to
cationic complexes 1 and 2. In case of ligand L2, NAH of
the picolinamide part of the ligand is deprotonated by metal
(Rh and Ir). Ligand L1 is neutral and L2 is anionic in naturer activity and structural studies of rhodium and iridium complexes featuring the
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14 N.R. Palepu et al.while forming their respective complexes. In complexes 5 and 6
the pyridine of the pyridin-2-ylmethylene part of the ligand acts
as bridging and is responsible for the substitution of the metal
chloride and consequently forming dinuclear complexes.
Complexes 1 and 2 have shown moderate apoptosis activity
against Dalton’s ascites lymphoma cells with 22% and
30% apoptotic cell death. Though the cytotoxicity of com-
plexes 1 and 2 against DL cells is comparatively lesser than
that of cisplatin, their less cytotoxicity on normal cells (PBMC)
could take them forward to implement as antitumor agents.
Complexes 1, 2, 5 and 6 are bactericidal against the two
bacteria species studied. All the four complexes have shown
high activity against V. parahaemolyticus (MTCC 451) where
the positive control amoxicillin itself is inactive. P. vulgaris is
more susceptible to iridium complexes (complexes 2 and 6).
V. parahaemolyticus (MTCC 451) is equally susceptible
to rhodium and iridium complexes (complexes 1 and 6).
Complex 5 has shown the least activity among the four
complexes against the two bacterial species.
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